Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Equity Average (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Equity Average for 13 consecutive years, with $18.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 38.32% to $18.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.7 million, a 38.32% decrease, with the full-year FY2025 number at $23.3 million, down 30.4% from a year prior.
  • Equity Average was $18.7 million for Q4 2025 at Aytu Biopharma, down from $21.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $124.5 million in Q3 2021 to a low of $18.7 million in Q4 2025.
  • A 5-year average of $46.3 million and a median of $34.3 million in 2023 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: crashed 62.8% in 2022, then grew 3.2% in 2025.
  • Aytu Biopharma's Equity Average stood at $108.5 million in 2021, then crashed by 56.61% to $47.1 million in 2022, then crashed by 30.95% to $32.5 million in 2023, then decreased by 6.81% to $30.3 million in 2024, then tumbled by 38.32% to $18.7 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Equity Average are $18.7 million (Q4 2025), $21.1 million (Q3 2025), and $26.9 million (Q2 2025).